Dr. Usmani on Emerging Treatment Strategies in Late Relapsed Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses emerging treatment strategies in late relapsed multiple myeloma.

Novel treatment options like cereblon E3 ligase modulators are being evaluated for patients with late relapsed multiple myeloma, Usmani says. Additionally, combination regimens with selinexor (Xpovio) are being developed.

Venetoclax (Venclexta)-based regimens are also under investigation for patients with translocation 11;14–positive or BCL-2–overexpressing, late relapsed multiple myeloma, Usmani says. Ultimately, several small molecule and oral immunomodulatory therapies are emerging in late relapsed multiple myeloma to complement immunotherapeutic advances, Usmani concludes.